Search

Displaying results 1441 - 1450 of 8573 in total
  1. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  2. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    compared to earlier estrogen receptor modulators such as [tamoxifen]. … [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]

  3. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized

  4. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    It has one chiral center and is the R-stereoisomer.[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54141] Nerandomilast exerts both anti-fibrotic and immunomodulatory effects as PDE4 inhibition elevates intracellular cAMP levels and reduces the expression of pro-fibrotic growth factors and inflammatory

  5. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is

  6. Drug

    Levosalbutamol

    go.drugbank.com/drugs/DB13139
    Approved

    [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. … The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol

  7. Drug

    Pentagastrin

    go.drugbank.com/drugs/DB00183
    Approved

    It has also been used as a diagnostic aid.

  8. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    Dihydroergotamine is used as an abortive therapy for migraines. … [L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.

  9. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    This drug has also been used for management of hypertriglyceridemia [L1503]. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.

  10. Drug

    Lincomycin

    go.drugbank.com/drugs/DB01627
    ApprovedInvestigationalVet approved

    [A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] … [A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains

    Products: LINCOMYCIN INJECTION 600MG/2ML, LINCOSA INJECTION 300MG/ML